Patients in Clinical Studies Report 100% Satisfaction
MARLBOROUGH, Massachusetts,
Oct. 17, 2017 /PRNewswire/ --
Hologic, Inc. (Nasdaq: HOLX) announced today that it has received
an additional European Medical Device Directive (MDD) certification
for SculpSure®, a state-of-the-art body contouring laser treatment.
The device is now certified to treat a double chin (also known as
the submental area), marking the product's sixth certified body
treatment area. SculpSure® is also certified to treat the abdomen,
love handles (flanks), back, and inner and outer thighs.
The certification allows Hologic to place the CE Mark on
SculpSure® double chin (submental) treatments for use in the
European Union (EU) and its member states. The double chin
(submental) treatment requires practitioners to purchase a simple
laser attachment, which will allow the treatment applicators to fit
seamlessly onto the area. Hologic's Cynosure sales force will begin
distribution immediately to interested practitioners.
"Most patients in the 57-person submental clinical trial
received two brief treatments six weeks apart," said Dr.
Lawrence Bass, board certified
plastic surgeon and a principal investigator in the SculpSure
clinical trials. "The short treatment time, 100% satisfaction rate,
and dramatic contour reductions typically seen in the study
patients give SculpSure the edge as the treatment of choice for the
submental area."
SculpSure® is an advanced, non-invasive body contouring
treatment that helps patients achieve a natural-looking, slimmer
appearance. The fully customizable treatment uses a laser to raise
the temperature of body fat to precisely disrupt and destroy fat
cells under the skin. The fat cells are then naturally eliminated
over time and do not return. Each treatment lasts approximately 25
minutes and requires no surgery or downtime.
"The receipt of the CE Mark to treat double chin is an important
growth milestone for SculpSure®," said Kevin Thornal, Divisional President of Cynosure
at Hologic. "The laser's proven effectiveness rate coupled with the
fact that SculpSure® is certified to treat patients with a wider
BMI range than our competition in the submental area will provide
healthcare professionals with a distinct treatment advantage that
can drive demand and widen their patient communities."
To learn more about SculpSure® or visit SculpSure.com.
About Hologic, Inc.
Hologic, Inc. is an innovative
medical technology company primarily focused on improving women's
health and well-being through early detection and treatment.
For more information on Hologic, visit www.hologic.com.
Hologic, The Science of Sure and SculpSure are registered
trademarks of Hologic, Inc. in the United
States and/or other countries.
Forward-Looking Statements
This news release may
contain forward-looking information that involves risks and
uncertainties, including statements about the use of Hologic
products. There can be no assurance these products will achieve the
benefits described herein or that such benefits will be replicated
in any particular manner with respect to an individual patient, as
the actual effect of the use of the products can only be determined
on a case-by-case basis. In addition, there can be no assurance
that these products will be commercially successful or achieve any
expected level of sales. Hologic expressly disclaims any obligation
or undertaking to release publicly any updates or revisions to any
such statements presented herein to reflect any change in
expectations or any change in events, conditions or circumstances
on which any such data or statements are based.
Media Contact
Jane
Mazur
508.263.8764 (direct)
585.355.5978 (mobile)
jane.mazur@hologic.com
Investor Contact
Michael
Watts
858.410.8588
michael.watts@hologic.com